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Research Article
Endogenous epitope-tagging of Tet1, Tet2 and Tet3
identiﬁes TET2 as a naı¨ve pluripotency marker
Raphae¨l Pantier , Tülin Tatar, Douglas Colby, Ian Chambers
Tet1, Tet2, and Tet3 encode DNA demethylases that play critical
roles during stem cell differentiation and reprogramming to
pluripotency. Although all three genes are transcribed in plu-
ripotent cells, little is known about the expression of the cor-
responding proteins. Here, we tagged all the endogenous Tet
family alleles using CRISPR/Cas9, and characterised TET protein
expression in distinct pluripotent cell culture conditions.
Whereas TET1 is abundantly expressed in both naı¨ve and primed
pluripotent cells, TET2 expression is restricted to the naı¨ve
state. Moreover, TET2 is expressed heterogeneously in embry-
onic stem cells (ESCs) cultured in serum/leukemia inhibitory
factor, with expression correlating with naı¨ve pluripotency
markers. FACS-sorting of ESCs carrying a Tet2Flag-IRES-EGFP re-
porter demonstrated that TET2-negative cells have lost the
ability to form undifferentiated ESC colonies. We further show
that TET2 binds to the transcription factor NANOG. We hy-
pothesize that TET2 and NANOG co-localise on chromatin to
regulate enhancers associated with naı¨ve pluripotency genes.
DOI 10.26508/lsa.201900516 | Received 7 August 2019 | Revised 19 September
2019 | Accepted 19 September 2019 | Published online 3 October 2019
Introduction
Ten-eleven translocation (TET) family proteins are responsible for
active DNA demethylation by sequential oxidation of 5-methyl-
cytosine into 5-hydroxymethylcytosine, 5-formylcytosine, and 5-
carboxylcytosine (1, 2). TET proteins contribute to DNA demethylation
in naı¨ve embryonic stem cells (ESCs) (3, 4, 5, 6) and their activity is
required both for proper differentiation (7, 8) and for reprogramming
to pluripotency (9). TET proteins are also critical for embryonic de-
velopment, as Tet1/2/3 triple-knockout embryos cannot proceed
beyond gastrulation (10).
Although genetic studies indicate that TET proteins have re-
dundant activities, the low level of sequence conservation outside
the catalytic domain suggests that they may also exert distinct
functions (11, 12). Indeed, Tet1, Tet2, and Tet3 have different ex-
pression patterns during development and in adult tissues (13). TET
proteins also interact with partner proteins such as OGT and Sin3a
complex members, which might promote functions independent of
TET catalytic activity (14, 15, 16, 17).
Because of the lack of reliable commercial antibodies and re-
porter systems, TET protein expression, particularly at the single
cell level, remains poorly characterized. In this study, we used
CRISPR/Cas9 in ESCs to tag all endogenous Tet1, Tet2, and Tet3
alleles with antibody epitopes and ﬂuorescent reporters. These
cellular reagents allowed the visualisation and the functional
analysis of TET proteins in pluripotent cells.
Results
TET proteins present distinct expression patterns in ESCs
To visualise endogenous TET protein expression in ESCs, we
generated knockin alleles using CRISPR/Cas9. Donor templates
(targeting vectors or single-stranded oligonucleotides) were used
to add epitope tags in frame with the TET protein coding se-
quences (Figs 1A and ﬁg S1 for a summary of all cell lines). Initially,
a targeting vector containing a puromycin resistance cassette
(PuroR) was used to add the triple Flag epitope tag (Flag)3 at the
C-terminus of TET1, resulting in the generation of heterozygous
Tet1Flag-IP/+ ESC clones (Fig S2). To obtain a cell line expressing
only tagged versions of TET1, the remaining wild-type allele of
Tet1Flag-IP/+ clone C10 was re-targeted using a vector with an EGFP
reporter to give Tet1Flag-IP/Flag-IGFP cells (Fig S3). For subsequent
modiﬁcations of Tet alleles, single-stranded DNA (ssDNA) oligo-
nucleotides were used as donor templates for homologous re-
combination, as they result in high targeting efﬁciencies and do
not require the use of a selection cassette (18). This alternative
strategy was used to fuse a V5 epitope to the C terminus of TET2 in
Tet1Flag-IP/Flag-IGFP clone C1 (Fig S4). In clones C2 and C3, both Tet2 alleles
were successfully modiﬁed in a single step, resulting in the generation
of double-tagged Tet1Flag-IP/Flag-IGFP;
Tet2V5/V5 ESC clones. To generate an ESC line carrying all six modiﬁed
Tet alleles, Tet1Flag-IP/Flag-IGFP; Tet2V5/V5 clone C3 was modiﬁed using a
ssDNA that fused a HA tag to the C terminus of TET3. PCR genotyping
identiﬁed two Tet1Flag-IP/Flag-IGFP; Tet2V5/V5; Tet3HA/HA clones (Fig S5), and
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Sanger sequencing conﬁrmed that clone C7 has both Tet3 alleles
appropriately modiﬁed, which we refer to as Tettag/tag ESCs.
To investigate the expression proﬁle and single cell heterogeneity
of TET1, TET2, and TET3 proteins, we performed immunoﬂuorescence
analyses on Tettag/tag ESCs using antibodies recognising ﬂag (TET1),
V5 (TET2), or HA (TET3) epitope tags. In serum/Leukemia inhibitory
factor (LIF), TET1 is expressed in most cells at relatively homogenous
levels within the population (Fig 1B). In contrast, TET2 is heteroge-
neously expressed with a “salt and pepper” pattern composed of a
mixture of TET2-positive and TET2-negative ESCs (Fig 1B). TET3 was
undetectable (Fig 1B). To further explore TET protein expression in the
naı¨ve state, we cultured Tettag/tag ESCs in the presence of LIF and
inhibitors of MEK and GSK3β (2i/LIF). In this condition, ESCs form
dome-shaped colonies and homogenously express naı¨ve pluripo-
tency markers (19). In 2i/LIF, both TET1 and TET2 present a more
homogenous expression pattern (Fig 1C). Once again TET3 protein
was undetectable (Fig 1C). These data on TET protein expression are
in accord with the relative expression of Tet mRNAs (Fig S6A and B).
Interestingly, all Tet mRNAs are expressed at lower levels in 2i/LIF
than serum/LIF.
Although the preceding analyses demonstrated that TET family
proteins are differentially expressed in ESCs, the use of different
epitope tags did not allow a direct comparison of expression
levels of different TET proteins. Therefore, to allow the relative
quantiﬁcation of TET1 and TET2 proteins, we targeted Tet1 in
E14Tg2a ESCs with an ssDNA to introduce the V5 epitope tag (Fig
S7A). Two clones in which both Tet1 alleles were tagged by V5 were
obtained (Fig S7B). We next performed comparative analyses of
Tet1V5/V5 ESCs with Tettag/tag ESCs in which an identical V5 epitope
tag was fused to TET2. We conﬁrmed that both cell lines retain
similar self-renewal efﬁciencies as wild-type E14Tg2a ESCs (Fig
S8A) and express normal levels of the pluripotency factor NANOG
(Fig S8B and C). Comparative immunostaining of Tet1V5/V5 ESCs
with Tettag/tag ESCs using a V5 antibody showed that TET1 is
expressed at much higher levels than TET2 in serum/LIF (Fig 1D).
Consistent with low protein abundance, TET2 was undetectable by
Western blot but could be detected after enrichment by immu-
noprecipitation, showing a band at the predicted size (210 kD) for
the full-length TET2-V5 protein (Fig S6C).
Together, these analyses revealed for the ﬁrst time the relative
expression of TET proteins expression at the single cell level in ESCs.
Figure 1. TET protein expression and heterogeneity
in ESCs.
(A) General strategy for generating tagged Tet knockin
alleles. ESCs were co-transfected with a gRNA designed
near the stop codon and a repair template (single-
stranded oligo or targeting vector) containing an
epitope tag (Flag, V5 or HA). (B, C) Immunoﬂuorescence
for Flag (TET1, red), V5 (TET2, yellow), and HA (TET3,
magenta) in Tettag/tag ESCs cultured in serum/LIF (B) or
2i/LIF (C). (B) Wild-type E14Tg2a ESCs transfected with
an HA-NANOG expression plasmid provided a
positive control (B). Scale bars: 50 μm. (D)
Immunoﬂuorescence for V5 (yellow) in Tet1V5/V5 ESCs
(top) and Tettag/tag ESCs (bottom) cultured in serum/
LIF. Samples were imaged and processed under the
same conditions to allow a direct comparison of TET1
and TET2 expression levels. Scale bars: 50 μm.
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TET2 marks self-renewing ESCs in serum/LIF
To further characterise TET2 function, we generated a Tet2Flag-IRES-
EGFP reporter cell line from E14Tg2a ESCs. After transfection with
CRISPR/Cas9 and a targeting vector, EGFP+ ESCs were sorted into
single wells and expanded (Fig S9A). PCR analyses identiﬁed nine
ESC clones in which (Flag)3-IRES-EGFP was targeted to the 39 end
of Tet2 (Fig S9B). Of these, four clones did not produce PCR
products of wild-type alleles, indicating that both Tet2 alleles
were modiﬁed (Fig S9C). Co-immunoﬂuorescence analysis of ESCs
cultured in serum/LIF conﬁrmed the heterogeneous TET2 ex-
pression pattern and indicated that TET2 (Flag) expressing cells
were also ﬂuorescently marked by the cytoplasmic EGFP tran-
scriptional reporter (Fig 2A). FACS of ESCs cultured in serum/LIF
allowed the selection of Tet2Flag-IRES-EGFP cells based on their TET2
expression level, using the nonﬂuorescent parental cell line
(E14Tg2a) as a negative control (Figs 2B and Fig S10). To investigate
the self-renewal efﬁciency of ESCs expressing distinct TET2 levels,
ESCs cultured in serum/LIF were FACS-sorted into TET2-positive
and TET2-negative populations. The cells were then plated at
clonal density and stained for AP following 7 d of culture in serum/
LIF condition. Strikingly, TET2-negative ESCs formed almost no
self-renewing ESC colonies (Fig 2C). In contrast, TET2-positive ESCs
showed a similar number and proportion of AP-stained colonies
compared with the bulk-sorted control and parental cell lines (Fig
2C).
To examine transcriptional differences between TET2-positive
and TET2-negative ESC populations, quantitative reverse tran-
scription PCR (RT-qPCR) analysis was performed on selected
transcripts (Fig 2D). As expected, Tet2 mRNA expression was high
in TET2-positive ESCs, and dramatically decreased in TET2-
negative ESCs. The transcript levels of the pluripotency factor
Oct4 were decreased by 50% in TET2-negative ESCs compared with
the bulk-sorted control or the parental cell line. This reduction
was more pronounced with the naı¨ve markers Nanog and Esrrb.
Together, these data suggest that TET2 expression is tightly
associated with naı¨ve pluripotency marker expression and efﬁcient
ESC self-renewal.
Figure 2. TET2marks self-renewing ESCs in serum/LIF
culture condition.
(A) Co-immunoﬂuorescence for Flag (TET2, yellow) and
EGFP (green) in Tet2Flag-IRES-EGFP ESCs cultured in serum/
LIF. Scale bar: 50 μm. (B) General strategy for sorting
TET2-EGFP–positive and TET2-EGFP–negative Tet2Flag-
IRES-EGFP ESCs. (C) Clonal self-renewal assays of FACS-
sorted Tet2Flag-IRES-EGFP ESCs (or the wild-type
parental cell line). Error bars: SD of the mean (n = 3).
(D) Quantitative mRNA expression in FACS-sorted
Tet2Flag-IRES-EGFP ESCs, compared with the wild-type
parental cell line. Error bars: SD of the mean (n = 2).
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TET2 interacts with NANOG and co-localises at ESC enhancers
NANOG is heterogeneously expressed in ESCs and its expression
level is directly related to self-renewal efﬁciency (20, 21). As both
TET2 and NANOG behave as naı¨ve pluripotency markers and were
reported to interact with each other (22), we further investigated the
relationship between these two proteins.
To compare the expression patterns of TET2 and NANOG, we
performed co-immunoﬂuorescence in ESCs grown in serum/LIF (Fig
3A). Quantitation of immunoﬂuorescence in single cells showed
that the vast majority of TET2-positive cells co-express NANOG (Fig
3B). This observation further conﬁrms the correlation between TET2
and NANOG that we identiﬁed at themRNA expression level (Fig 2D).
However, TET2 marks a larger population of cells than NANOG,
resulting in the detection of TET2+/NANOG− ESCs (Fig 3A and B).
To examine the physical interaction between TET2 and NANOG,
we performed co-immunoprecipitations in ESCs using differently
truncated TET2 constructs (Fig S11A). Interestingly, both TET2 N
terminus (1–1,221) and C terminus (924–1,911) interact with NANOG
(Fig S11B). Non-overlapping TET2 truncations (1–828 and 924–1,377)
retained their interaction with NANOG (Fig S11C). This suggests the
presence of at least two NANOG-binding regions within TET2. In-
terestingly, the stronger interaction with full-length TET2 compared
with TET2 N- and C-terminal fragments (Fig S11C), suggests that
NANOG-binding regions act in a cooperative manner.
To further explore the interaction between TET2 and NANOG, we
investigated the chromatin-binding proﬁle of these two proteins
in ESCs. Previously published TET2 (23) and NANOG (24) ChIP-seq
datasets were analysed and compared, with a particular focus on
the pluripotency gene regulatory network which controls ESC self-
renewal (25). TET2 and NANOG ChIP-seq signals (and their re-
spective input controls) were visualised as heat maps at ESC
enhancers, deﬁned as sites co-bound by OCT4-SOX2-NANOG (24).
Both TET2 and NANOG are centrally enriched at ESC enhancers (Fig
3C). To validate this observation, we examined TET2 and NANOG
ChIP-seq signal at relevant pluripotency genes (Nanog, Oct4,
Esrrb, Klf4, and Prdm14) using a genome browser. Interestingly,
TET2- and NANOG-binding proﬁles are highly similar at these loci
with most peaks co-localising within ESC “super-enhancers” (24)
(Fig 3D).
Figure 3. TET2 interacts with NANOG and co-localises
at ESC enhancers.
(A) Co-immunoﬂuorescence for Flag (red) and NANOG
(green) in Tet2Flag-IRES-EGFP ESCs cultured in serum/LIF.
Scale bar: 50 μm. (B) Quantiﬁcation of TET2/NANOG
co-immunoﬂuorescence (as in panel [A]) in four
independent Tet2Flag-IRES-EGFP ESC clones cultured in
serum/LIF. For each clone, nuclei were counted in
two independent ﬁelds of view. (C) Heat maps showing
NANOG (24) and TET2 (23) RPKM-normalised ChIP-seq
signal at ESC enhancers. (D) Genomic snapshots
showing TET2 (red) and NANOG (green) ChIP-seq signal
at selected pluripotency loci. Blue bars: ESC super-
enhancers (24).
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Together, these results indicate that TET2 and NANOG physically
interact and co-localise on chromatin to regulate the pluripotency
gene regulatory network.
TET proteins are dynamically expressed during the transition
from naı¨ve to primed pluripotency
Recent studies demonstrated that ESCs can be driven from a naı¨ve
to a primed pluripotent state in vitro, reﬂecting a change from a
pre- to post-implantation epiblast molecular signature. This
transition is accompanied by global epigenomic and transcriptional
changes (26), to which TET proteins might contribute (27).
To examine the expression of Tet family genes in the primed plu-
ripotent state, we used two different culture systems: Epiblast-like cells
(EpiLC) (28) and Epiblast stem cells (EpiSC) (29). First, we examined the
mRNA levels of Tet1, Tet2, and Tet3 by RT-qPCR (Fig 4A). In EpiLCs (24
and 48 h), Tet1 transcript levels are similar to naı¨ve ESCs cultured in
2i/LIF. In contrast, Tet1mRNA is decreased by threefold to ﬁvefold in
EpiSCs compared with ESCs cultured in serum/LIF and 2i/LIF, re-
spectively. Tet2 transcripts are dramatically decreased both in EpiLCs
and EpiSCs comparedwith ESCs, further conﬁrming that Tet2 behaves
as a naı¨ve pluripotency marker. In EpiLCs (48 h) and EpiSCs, Tet3 is
transcribed at levels which are similar to ESCs cultured in serum/LIF,
where TET3 protein is undetectable (Fig 1B).
To extend our analysis to the expression of TET proteins in the
primed state, we performed EpiLC and EpiSC differentiation with our
Tettag/tag ESC line, followed by immunoﬂuorescence for TET1 (Flag),
TET2 (V5), or TET3 (HA), together with the control marker OCT6 (26).
Both in EpiLCs (Fig 4B) and in EpiSCs (Fig 4C), TET1 was the only
detected protein, showing a homogenous expression pattern.
However, a long exposure time was required to image TET1 in
EpiSCs, indicating a lower expression level than EpiLCs/ESCs and
conﬁrming the results from RT-qPCR analysis (Fig 4A).
To further explore changes in TET protein expression during the
transition from naı¨ve to primed pluripotency, we performed a time
course EpiSC differentiation experiment with Tettag/tag ESCs. Sur-
prisingly, TET1 protein showed highly dynamic changes (Fig 4D). Up
to day 3 of the EpiSC differentiation protocol, TET1 expression was
progressively lost in the whole population. On day 4, both TET1 and
NANOG were re-expressed at high levels in a subset of cells, which
Figure 4. TET protein dynamics during the transition
from naı¨ve to primed pluripotency.
(A) Quantitative mRNA expression in E14Tg2a ESCs
cultured in naı¨ve conditions (serum/LIF or 2i/LIF) and
differentiated into primed EpiLCs (24 and 48 h) or
EpiSCs (passage 15). Error bars: SD of the mean (n ≥ 2).
(B, C) Co-immunoﬂuorescence for OCT6 (green) and
Flag (TET1, red) or V5 (TET2, yellow) or HA (TET3,
magenta) in Tettag/tag EpiLCs (48 h) (B) or in Tettag/tag
EpiSCs (passage 11) (C) cultured in activin/FGF.
Scale bars: 50 μm. (D) Time course co-
immunoﬂuorescence for Flag (TET1, red) and NANOG
(green) in Tettag/tag cells during EpiSC differentiation
(arrow) from serum/LIF culture condition. Samples
were imaged and processed under the same
conditions to allow a direct comparison of TET1 and
NANOG expression levels between different time
points. Scale bars: 50 μm.
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may mark future EpiSCs, as TET1 and NANOG expression was ho-
mogenous by passage 3 (at lower levels than day 4). Interestingly,
TET2 followed a similar expression dynamics during early EpiSC
differentiation (Fig S12A), although its expression was completely
lost in stable EpiSCs (Fig 4C). In contrast, TET3 remained un-
detectable throughout EpiSC differentiation (Fig S12B). A similar
time course immunoﬂuorescence experiment was performed in
Tettag/tag cells during EpiLC differentiation (from 24 to 72 h). This
analysis did not reveal any change in TET1 protein expression
compared with 2i/LIF (Fig S13A), whereas TET2 and TET3 could not be
detected at any time point (Fig S13B and C), in agreement with their
low transcription levels (Fig 4A).
Together, these experiments revealed dynamic changes in TET
protein expression during the transition from naı¨ve to primed
pluripotency.
Discussion
In this study, we comparatively assessed the expression of all Tet
family genes in pluripotent cells. Immunoﬂuorescence analyses
revealed that TET1 protein is expressed in both naı¨ve and primed
pluripotent cells, whereas TET2 is exclusively expressed in naı¨ve
ESCs. Furthermore, TET1 is homogeneously expressed in serum/LIF,
whereas TET2 is expressed only in a subset of cells. This differential
expression suggests that TET1 and TET2 might exert distinct func-
tions in pluripotent cells, which is supported by recent studies.
Knockdown experiments indicated that TET1 and TET2 control the
methylation of distinct genomic regions in ESCs (11). In addition, the
ectopic expression of TET2 (but not TET1) reprograms cells from
primed to naı¨ve pluripotency (12).
Our work indicated that TET2 is a naı¨ve pluripotency marker. In
serum/LIF, TET2 speciﬁcally marks self-renewing ESCs and is asso-
ciated with the expression of other heterogeneously expressed fac-
tors controlling the naı¨ve state like NANOG (21) and Esrrb (30).
Conversely, TET2-negative cells present low levels of naı¨ve pluripo-
tency markers and are unable to form AP-positive colonies. In ad-
dition, TET2 expression becomes homogenous during the transition
from serum/LIF to 2i/LIF, which maintains ESCs in a naı¨ve state.
Conversely, TET2 expression is abolished during the transition to the
primed state, either with the EpiLC or the EpiSC differentiation pro-
tocol. Further molecular characterisation on TET2-positive and TET2-
negative ESCs will be required to reveal genome-wide transcriptional
and methylation changes between these two cell populations.
We demonstrated that TET2 and NANOG aremostly co-expressed in
ESCs cultured in serum/LIF. This observation could be extended to the
analysis of TET2 expression in the inner cell mass of the pre-
implantation blastocyst, where NANOG presents a “salt and pepper”
expression pattern, which is critical to determine the balance between
epiblast and primitive endoderm (31). Furthermore, NANOG
transiently ﬂuctuates between high and low expression states in
ESCs (21). As TET2 is a direct transcriptional target of NANOG (32), its
expression might ﬂuctuate in a similar manner, explaining the
correlation between TET2 and NANOG expression in ESCs.
In this study, we have shown that TET2 physically interacts with
NANOG and co-localises at pluripotency enhancers. As TET2 lacks a
DNA-binding domain, it might be targeted by NANOG to these loci to
maintain them in a demethylated state. A recent study reported that
TET2 could be efﬁciently ChIPed only after extensive cross-linking
with formaldehyde plus disuccinimidyl glutarate (33), suggesting that
TET2 interacts indirectly with chromatin. TET2 localises to completely
different loci in ESCs and hematopoietic cells (33), supporting a
model in which TET2 is targeted to chromatin via protein–protein
interactions in a context-dependent manner. In contrast, TET1 has a
CXXC domain, which recruits this protein mostly to CpG islands (17,
34). Supporting this model, Tet2 knockout causes hypermethylation
of enhancers in ESCs, whereas Tet1 knockout has no effect on the
methylation status of these genomic regions (35). More recently, TET2
was shown to promote enhancer demethylation by interacting with
C/EBPα, Klf4 and Tfcp2l1 at distinct stages of induced pluripotent
stem cell reprogramming (36).
Here, time course experiments allowed the visualisation of TET
expression changes during the transition from naı¨ve to primed
pluripotency. Interestingly, TET1/2 and NANOG showed similar dy-
namics during early EpiSC differentiation. The global and transient
decrease in NANOG/TET expression might mark the recently de-
scribed “formative” pluripotent state (37). However, TET proteins did
not show dynamic expression changes during EpiLC differentiation,
which might be explained by a rapid and homogenous transition to
the primed state (28) without passing through a “formative” plu-
ripotent state. In addition, TET1 is expressed at higher levels in EpiLCs
compared with EpiSCs. These observations highlight differences
between the EpiLC and EpiSC differentiation protocols.
In conclusion, we generated knockin alleles of Tet family genes
with epitope tags or ﬂuorescent reporters, providing a robust
characterisation of TET protein expression dynamics and single-cell
heterogeneity in pluripotent cells. The engineered ESC lines pro-
duced in this study could be further exploited to study TET1/2/3
protein expression in vivo in transgenic mouse models.
Materials and Methods
Cell culture
All the cell lines in this study were derived from E14Tg2a (38) and
incubated in a 37°C/7%CO2 incubator. ESCswere cultured on gelatin-
coated plates. Composition of the serum/LIF medium: Glasgow Min-
imum Essential Medium (Cat. no. G5154; Sigma-Aldrich), 10% fetal
bovine serum, 1× L-glutamine (Cat. no. 25030-024; Invitrogen), 1× py-
ruvate solution (Cat. no. 11360-039; Invitrogen), 1× MEM nonessential
amino acids (Cat. no. 11140-036; Invitrogen), 0.1 mM 2-mercaptoethanol
(ref. 31350010; Gibco), and 100 U/ml LIF (made in-house).
For 2i/LIF ESC culture (19), serum-free N2B27 medium was pre-
pared: 1:1 vol/vol mix of DMEM:F12 (Cat. no. 12634010; Gibco) and
Neurobasal (Cat. no. 21103049; Gibco), 1× L-glutamine (Cat. no.
25030-024; Invitrogen), 1× MEM nonessential amino acids (Cat. no.
11140-036; Invitrogen), 0.1 mM 2-mercaptoethanol (ref. 31350010;
Gibco), 1× N2 supplement (Cat. no. 17502048; Gibco), 1× B27 sup-
plement (Cat. no. 17504044; Gibco). 1 μM PD0325901 (Cat. no. 1408;
Axon), 3 μM CHIR99021 (Cat. no. 1386; Axon), and 100 U/ml LIF were
added freshly to the medium.
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EpiSC lines were derived in vitro from ESCs (29). 3 × 104 ESCs were
plated in a well of a six-wells plate with serum/LIF medium (see
composition above). After 24 h, the medium was switched to N2B27
medium (see composition above) supplemented with 20 ng/ml human
activin A (Cat. no. 120-14E; PeproTech) and 10 ng/ml human Fgf basic
(Cat. no. 233-FB-025/CF; R&D Systems). The cells were submitted to daily
media changes and passaged at day 5 of the protocol in six-well plates
coated with 7.5 μg/ml bovine ﬁbronectin. The cells were maintained in
N2B27 medium supplemented with Activin/Fgf and passaged every 2–3
d. Homogenous EpiSCs were derived within 10 passages.
EpiLC differentiation was performed as described in (39). ESCs
were adapted to 2i/LIF culture for at least three passages on poly-L-
ornithine (Cat. no. P3655; Sigma-Aldrich) and laminin-coated wells
(Cat. no. 354232; BD Biosciences) of a six-well plate. 2.5 × 105 ESCs
were plated on a well of six-well plate pretreated with 16.6 μl/ml
ﬁbronectin (Cat. no. FC010; Millipore) and containing EpiLC medium:
N2B27 medium (see the composition above) supplemented with 20
ng/ml human activin A (Cat. no. 120-14E; PeproTech), 12 ng/ml
human Fgf basic (Cat. no. 233-FB-025/CF; R&D Systems) and 1%
knockout serum replacement (Cat. no. 10828-028; Gibco). The cells
were submitted to daily media changes and collected for analyses.
Self-renewal assays
Cells were collected by trypsinisation and resuspended in PBS (Cat.
no. D8537; Sigma-Aldrich) supplemented with 2% fetal bovine serum
at a concentration of around 1 × 106 cells/ml. The cell suspension was
passed through a cell strainer and kept on ice until cell sorting (-
FACSAria II; Becton Dickinson). Single cells were gated using the
forward-scattered light and side-scattered light parameters. Auto-
ﬂuorescent (dead) cells were also discarded. Gates for selecting EGFP
ﬂuorescent cells (“GFP B 525/50”) were drawn using the non-
ﬂuorescent parental cell line (E14Tg2a ESCs) as a negative control.
Tet2 bulk and E14Tg2a WT control cells were processed by FACS with
no selection based on EGFP ﬂuorescence. 600 cells were directly
sorted in gelatin-coatedwells of six-well plates containing serum/LIF
medium (see the composition above). After 7 d of culture, the cells
were washed in PBS and incubated for 1 min in a ﬁxative solution
made by mixing 25 ml of citrate solution (18 mM citric acid, 9 mM
sodium citrate, and 12 mM NaCl), 8 ml of formaldehyde solution (37%
vol/vol in water), and 65 ml of acetone. Fixed cells were washed in
distilled water and stained for AP expression using a leukocyte AP kit
(Cat. no. 86R-1KT; Sigma-Aldrich). Colonies were counted and cat-
egorised according to their morphology and AP staining.
CRISPR-mediated homologous recombination
To modify endogenous Tet1/2/3 alleles, a double-strand break was
generated at desired genomic loci using Cas9 and a synthetic gRNA
(18). gRNAs were designed (http://crispr.mit.edu/) and cloned into
Cas9/gRNA co-expression plasmids (pX330; Addgene, or
derivatives).
To prevent cutting of targeted alleles by CRISPR/Cas9, donor
templates were designed so that the gRNA site is disrupted after
homologous recombination. Alternatively, a silent mutation was
added in the donor template to disrupt the gRNA PAM sequence
(NGG). Two types of donor templates were used for homologous
recombination: targeting vector or ssDNA oligonucleotide. Targeting
vectors were cloned by Gibson assembly into a pBluescript backbone
and contained a selection cassette (ﬂuorescent reporter or puro-
mycin resistance). The 59- and -39 homology arms (typical size around
1.5 Kb) were ampliﬁed by PCR from ESC genomic DNA. ssDNAs
(presenting around 60-bp homology arms) were ordered from In-
tegrated DNA Technologies as Ultramer DNA oligonucleotides.
1 × 106 ESCs were transfected using Lipofectamine 3000 (cat.
L3000008; Thermo Fisher Scientiﬁc), following the manufacturer’s
instructions, with both the Cas9/gRNA plasmid and the donor
template (targeting vector or ssDNA). After 48 h, ESCs were selected
either by FACS sorting (targeting vector with ﬂuorescent reporter or
ﬂuorescent Cas9) or by the addition of 0.75 μg/ml puromycin
(targeting vector with puromycin resistance cassette). ESC clones
were expanded in 24-well plates and genomic DNA was extracted
(Cat. no. 69506; QIAGEN) for genotyping Tet alleles. PCR genotyping
was performed using forward and/or reverse primers binding
outside the homology arms of the donor template, therefore
conﬁrming themodiﬁcation of the endogenous locus. PCR products
were submitted to Sanger sequencing to conﬁrm that the desired
modiﬁcation was added in frame with the Tet coding sequence.
Correctly targeted ESC clones were expanded, and frozen aliquots
were transferred to liquid nitrogen tanks for long term storage.
List of gRNAs used for tagging Tet alleles
Target locus gRNA site (not including PAM sequence)
Tet1 start codon TTTGGAAGGCTTTGCGGGGC
Tet1 stop codon TGCGGGACCCTACAATCGTT
Tet2 stop codon ACAACACATTTGTATGACGC
Tet3 stop codon AGCCGCTGGATCTAGGTGCC
List of genotyping primers
Target locus Primer sequence
Tet1 39 FW1 CTGATGTATCCCCCGAAGCC
Tet1 39 FW2 CCACGTCCTGCCACTATACC
Tet1 39 RV1 TCGGAGTTGAAATGGGCGAA
Tet1 39 RV2 GGGCTTCTTGTGGCATCTCT
Puro FW GCCGCGCAGCAACAGATGGAA
Puro RV ACCCACACCTTGCCGATGTC
EGFP RV AACTTCAGGGTCAGCTTGCC
Tet2 39 FW ACAGGGTCTGTGACTACGGA
Tet2 39 RV1 ACAGATGCTGTGACCTGTCC
Tet2 39 RV2 CTGTGTCCCACGGTTACACA
Tet3 39 FW CCGTGTCCTCTTACGCCTAC
Tet3 39 RV CATGAGGGCAAAAGCACCAC
Tet1 59 FW ACTCCGATGATCCTGCCTCT
Tet1 59 RV TCGGGGTTTTGTCTTCCGTT
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Immunoﬂuorescence analysis
Cells were washed with PBS and ﬁxed with 4% PFA for 10 min at
room temperature. After ﬁxation, the cells were washed with PBS
and permeabilised with a solution of PBS containing 0.3% (vol/
vol) Triton X-100 for 10 min at room temperature. Samples were
blocked in blocking buffer (PBS supplemented with 0.1% [vol/vol]
Triton X-100, 1% [wt/vol] BSA, and 3% [vol/vol] serum of the same
species as the secondary antibodies were raised in) for 1 h at room
temperature. After blocking, the samples were incubated with
primary antibodies diluted in blocking buffer overnight at 4°C.
After four washes with PBS containing 0.1% (vol/vol) Triton X-100,
the samples were incubated with ﬂuorescently labelled sec-
ondary antibodies diluted in blocking buffer for 1 h at room
temperature in the dark. The cells were washed four times with
PBS containing 0.1% (vol/vol) Triton X-100. DNA was stained with
DAPI for 5 min at room temperature. The cells were washed with
PBS for 5 min. The samples were imaged by ﬂuorescence mi-
croscopy (Ti-E; Nikon). Images were analysed and processed using
the software Fiji.
Immunoprecipitation
E14/T ESCs were used for producing proteins for immunopre-
cipitation, as they can replicate and propagate pPyCAG plasmids
which carry a polyoma origin of replication (20). 3 × 106 E14/T ESCs
were transfected using Lipofectamine 3000 (Cat. no. L3000008;
Thermo Fisher Scientiﬁc), following the manufacturer’s in-
structions, with 6 μg of pPYCAG plasmids carrying a construct of
interest.
E14/T ESCs were harvested 24 h after transfection. The cells
were trypsinised, pelleted (5 min, 393g, 4°C), and washed twice
with cold PBS before lysis in a swelling buffer (5 mM Pipes, pH 8,
and 85 mM KCl) freshly supplemented with 1× protease inhibitor
cocktail (Cat. no. 04 693 116 001; Roche) and 0.5% NP-40. After 20
min on ice with occasional shaking, nuclei were pelleted (10 min,
524g, 4°C) and resuspended in 1 ml of lysis buffer (20 mM Hepes,
pH 7.6, 350 mM KCl, 0.2 mM EDTA, pH 8, 1.5 mM MgCl2, and 20%
glycerol) freshly supplemented with 0.2% NP-40, 0.5 mM DTT, and
1X protease inhibitor cocktail (Cat. no. 04 693 116 001; Roche). The
material was transferred into nonstick microtubes (Cat. no.
LW2410AS; Alpha Laboratories) and supplemented with 150 U/ml
of Benzonase Nuclease (Cat. no. 71206; Novagen). The samples
were incubated on a rotating wheel for 30 min at 4°C. Tubes were
centrifuged (16,100g, 30 min, 4°C) and nuclear extracts were
collected in clean nonstick tubes. 30–50 μl of nuclear protein
extract was boiled in Laemmli buffer as input material.
For immunoprecipitations, 5 μg of V5 antibody (Cat. no. 14-
6796-80; eBioscience) or Flag antibody (Cat. no. F3165; Sigma-
Aldrich) was added to nuclear extracts. For negative controls, 5 μg
of normal mouse IgG was added to nuclear extracts. Samples
were incubated overnight at 4°C on a rotating wheel. 30 μl of
Protein G Sepharose beads (Cat. no. 17061801; GE Healthcare),
previously blocked with 0.5 mg/ml chicken egg albumin, were
added to nuclear extracts, followed by a 2-h incubation at 4°C on
a rotating wheel. The samples were washed ﬁve times in a lysis
buffer (20 mM Hepes, pH 7.6, 350 mM KCl, 0.2 mM EDTA, pH 8, 1.5
mM MgCl2, and 20% glycerol) freshly supplemented with 0.5% NP-
40 and 0.5 mM DTT. Between each wash, the samples were
centrifuged (400g, 1 min, 4°C). After the ﬁnal wash, beads were
boiled in Laemmli buffer to solubilise the immunoprecipitated
material.
Protein samples were loaded into 10% Bis-Tris Gels (Cat. no.
NW00102BOX; Novex) with 1X MOPS SDS running buffer (Cat. no.
B0001; Novex). 10 μl of SeeBlue Plus2 prestained protein standard
(Cat. no. LC5925; Invitrogen) was used to visualise the protein
molecular weight. The electrophoresis was performed at 160 V for
1 h. Proteins were transferred (overnight at 4°C) to a nitrocellulose
membrane at 150 mA constant current in the presence of a
transfer buffer containing 25 mM Tris, 0.21 M glycine, and 10%
methanol. The membrane was blocked for 1 h at room temper-
ature with 10% non-fat skimmed milk dissolved in PBS supple-
mented with 0.1% Tween. Then, the membrane was incubated for 1
h at room temperature with primary antibodies diluted to the
working concentration (see table) in 5% nonfat skimmed milk
dissolved in PBS supplemented with 0.1% Tween. The membrane
was washed three times with PBS supplemented with 0.1% Tween,
and incubated for 2 h at room temperature with LI-COR IRDye–
conjugated secondary antibodies diluted 1:5,000 in 5% nonfat
skimmed milk dissolved in PBS supplemented with 0.1% Tween.
The membrane was ﬁnally washed three times with PBS sup-
plemented with 0.1% Tween before analysis with the LI-COR
Odyssey FC imaging system.
Antibodies
Antibody Reference Working dilution (application)
Flag Cat. no. F1804; Sigma-Aldrich 1:500 (immunoﬂuorescence)
Flag Cat. no. F3165; Sigma-Aldrich 1:5,000 (Western blot)
HA Cat. no. sc-805; Santa Cruz 1:50 (immunoﬂuorescence)
V5 Cat. no. 14-6796-80; eBioscience 1:250 (immunoﬂuorescence), 1:1,000 (Western-blot)
NANOG Cat. no. 14-5761-80; eBioscience 1:500 (immunoﬂuorescence)
NANOG Cat. no. A300-397A; Bethyl Laboratories 1:2,000 (Western-blot)
Oct6 Cat. no. sc-11661; Santa Cruz 1:200 (immunoﬂuorescence)
EGFP Cat. no. Ab13970; Abcam 1:200 (immunoﬂuorescence)
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RT-qPCR analysis
Total RNA was isolated using the RNeasy Plus Mini Kit (cat. 74136;
QIAGEN), following the manufacturer’s instructions. The quantity
and purity of RNA samples were determined using a microvolume
spectrophotometer (ND-1000; NanoDrop). RNA was reverse tran-
scribed with SuperScript III (Cat. no. 18080044; Invitrogen) using
random hexamer oligonucleotides, following the manufacturer’s
instructions. Triplicate qPCR reactions were set up with the Takyon
SYBRMasterMix (Cat. no. UF-NSMT-B0701; Eurogentec) and analysed
using the Roche LightCycler 480 machine. For all qPCR primer pairs,
standard curves were performed to assess the ampliﬁcation efﬁ-
ciency and melting curves were generated to verify the production
of single DNA species.
ChIP-seq analysis
ChIP-seq datasets were analysed using the Galaxy platform: https://
usegalaxy.org/ (40). The bioinformatics workﬂow is available at the fol-
lowing address: https://usegalaxy.org/u/raf4579/w/workﬂow-chip-seq-1.
Raw sequencing data (FASTQ ﬁles) were downloaded from the NCBI’s
Gene ExpressionOmnibus database. Quality control was performedusing
thesoftware “FastQC” (41). Sampleswereﬁltered to removecontaminating
adapter sequences and low-quality reads (cutoff quality score >20.0).
Reads were mapped to the mouse mm9 reference genome using
“Bowtie2” (BAM ﬁle output) (42). Reads were mapped only to a unique
genomic location (k = 1). ChIP-seq peaks were called using the software
“MACS2” (BED ﬁle output) (43). The immunoprecipitated sample was
compared with the genomic input for identifying statistically signiﬁcant
binding sites (q value 0.05). To visualise ChIP-seq datasets on a genome
browser, mapped reads (BAM ﬁles) were converted into bigwig ﬁles using
“deepTools” (44). Data were normalised in “reads per kilobase million”
(RPKM) to allow the comparison between ChIP-seq datasets. Genomic
snapshots were taken using the genome viewer “IGV” (45). To visualise
ChIP-seq datasets as heat maps, the software “deepTools”was used (44).
RPKM-normalised bigwig ﬁles were aligned to ESC enhancers (24).
Data Availability
Previously published NANOG (24) and TET2 (23) high-throughput
sequencing data were obtained from the NCBI’s Gene Expression
Omnibus database: NANOG ChIP-seq (GSE44286), TET2 ChIP-seq
(GSE57700).
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900516.
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